Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $271 from $257 and keeps a Buy rating on the shares after the company reported Q4 EBITDA in line with its preannouncement and offered 2026 guidance whose midpoint was about 3% above the firm’s and investor expectations into the print.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $257 from $240 at Barclays
- Tenet Healthcare price target raised to $288 from $260 at UBS
- Tenet Healthcare price target raised to $260 from $240 at BofA
- Tenet Healthcare price target raised to $242 from $230 at TD Cowen
- Tenet Healthcare price target raised to $260 from $247 at Morgan Stanley